The
ATP monitoring assay is a useful
biomarker for risk monitoring to detect
infection and rejection episodes in transplant recipients.
Hemodialysis patients have a higher rate of infectious mortality.
Infections in
hemodialysis patients are mainly caused by venous
catheters,
uremia,
malnutrition and
inflammation. However, the risk of
infection episodes has not been evaluated using a lymphocyte
ATP monitoring assay in
hemodialysis and
chronic kidney disease (CKD) patients. We measured the
ATP amounts in the peripheral CD4+ cells of CKD (N = 85) and dialysis patients (N = 17) using an "Immuknow" assay kit. These CKD patients were divided, according to
kidney disease stage, into G3a, G3b, G4, and G5 groups. The
ATP amounts in CD4+ cells of the dialysis patients and each of the CKD groups were compared with healthy subjects. In both the dialysis and CKD patients, the
ATP amounts in CD4+ cells were lower than in healthy subjects. Furthermore, there were significant differences in the
ATP amounts between healthy subjects and each of the CKD-G3a, CKD-G3b, and CKD-G4 groups (P < 0.05). Patients with CKD-G3a, CKD-G3b and CKD-G4 were evaluated as being at high risk for
infection according to the lymphocyte
ATP monitoring assay. However, the
ATP amounts in the dialysis and CKD-G5 patients did not differ from those in healthy subjects to a statistically significant extent. These results suggest that the
ATP amount in the CD4+ cells of these patients with serve
renal failure are influenced by dialysis treatment,
uremia and/or oxidative stress.